Diffuse Large B-cell Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Xynomic Pharma, Hanmi Pharma, S IMV Inc. Seagen

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diffuse Large B-cell Lymphoma pipeline constitutes 70+ key companies continuously working towards developing 75+ Diffuse Large B-cell Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Diffuse Large B-cell Lymphoma Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diffuse Large B-cell Lymphoma Market.

The Diffuse Large B-cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Diffuse Large B-cell Lymphoma Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Diffuse Large B-cell Lymphoma treatment therapies with a considerable amount of success over the years.

*
Diffuse Large B-cell Lymphoma companies working in the treatment market are Ubix Therapeutics, Otsuka Pharmaceutical Co., Ltd, Biomea Fusion Inc, Autolus Limited, Xynomic Pharmaceuticals, Inc., Hanmi Pharmaceutical, S IMV Inc. Seagen Inc., Zai Lab, Genentech, and others, are developing therapies for the Diffuse Large B-cell Lymphoma treatment

*
Emerging Diffuse Large B-cell Lymphoma therapies in the different phases of clinical trials are- UBX-303, OPB-111077, BMF-219, AUTO3, Abexinostat, Poseltinib, Maveropepimut, Brentuximabvedotin, Odronextamab, Mosunetuzumab, and others are expected to have a significant impact on the Diffuse Large B-cell Lymphoma market in the coming years.

*
In May 2025, Merck & Co (MSD)'s antibody-drug conjugate, zilovertamab vedotin, developed for the treatment of diffuse large B-cell lymphoma (DLBCL), has shown encouraging results in a Phase II/III clinical trial, positioning the company to potentially rival ADC Therapeutics' already approved therapy.

*
In March 2025, The FDA has granted Fast Track designation to azer-cel, an allogeneic, off-the-shelf CD19-targeted CAR T-cell therapy, for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Currently, a Phase 1b clinical trial (NCT03666000) is ongoing to assess azer-cel in individuals with relapsed or refractory non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia. This multicenter, open-label, nonrandomized trial involves dose escalation and expansion to evaluate the safety and clinical efficacy of the therapy in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma.

*
In February 2025, Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has launched waveLINE-010, a pivotal Phase 3 clinical trial assessing zilovertamab vedotin in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) against rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for previously untreated diffuse large B-cell lymphoma (DLBCL). Zilovertamab vedotin is Merck's investigational antibody-drug conjugate (ADC) designed to target receptor tyrosine kinase-like orphan receptor 1 (ROR1).

*
In December 2024, Genmab A/S (Nasdaq: GMAB) has released new long-term findings from two ongoing clinical trials assessing epcoritamab, a subcutaneously administered T-cell engaging bispecific antibody, in adult patients with diffuse large B-cell lymphoma (DLBCL). Data from Arm 1 of the Phase 1b/2 EPCORE Registered NHL-2 trial (NCT04663347) showed that fixed-duration epcoritamab combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) achieved a 100% overall response rate (ORR) and an 87% complete response (CR) rate in high-risk, previously untreated DLBCL patients (n=46).

*
In November 2024, Novotech, a leading global full-service clinical Contract Research Organization (CRO), continues to strengthen its role in oncology research by providing new insights into the global clinical trial landscape for Diffuse Large B-Cell Lymphoma (DLBCL). The company, which collaborates with biotech firms to advance novel therapeutics across all phases, highlights the promising progress of Phase III trials for Mosunetuzumab and Selinexor, particularly in patients with relapsed or refractory DLBCL.

*
In June 2024, Pfizer Inc. (NYSE: PFE) reported detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS Registered (brentuximab vedotin) combined with lenalidomide and rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study indicated that this combination reduced the risk of death by 37% compared to a placebo combined with lenalidomide and rituximab (HR 0.63 [95% CI: 0.445-0.891], p=0.0085). The OS benefit was consistent across all levels of CD30 expression. These results will be presented as a late-breaking abstract (LBA7005) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, alongside four-year results from the Phase 3 HD21 trial in advanced classical Hodgkin lymphoma (cHL) (LBA7000).

*
In April 2024, Roche has disclosed findings from the Phase III STARGLO trial demonstrating that its treatment Columvi (glofitamab), in combination with gemcitabine and oxaliplatin (GemOx), enhanced overall survival (OS) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This multicenter, open-label, randomized study evaluated the safety and effectiveness of Columvi plus GemOx versus MabThera/Rituxan (rituximab) combined with GemOx.

*
In March 2024, GenFleet Therapeutics has entered into a clinical trial collaboration and supply agreement with BeiGene Switzerland to initiate a Phase Ib/II clinical trial combining GFH009 and BRUKINSA (zanubrutinib) for the treatment of diffuse large B cell lymphoma (DLBCL). GFH009 is a cyclin-dependent kinase 9 (CDK9) inhibitor developed by GenFleet, while BRUKINSA is a Bruton's tyrosine kinase (BTK) inhibitor from BeiGene.

Diffuse Large B-cell Lymphoma Overview

Diffuse Large B-cell Lymphoma (DLBCL) is the most common and aggressive type of non-Hodgkin lymphoma, originating from abnormal B lymphocytes. It typically grows rapidly in lymph nodes but can also affect other organs. Symptoms may include swollen lymph nodes, fever, weight loss, and night sweats. DLBCL is considered treatable and potentially curable, especially when diagnosed early, with standard therapies like R-CHOP (a combination of chemotherapy and immunotherapy).

Get a Free Sample PDF Report to know more about Diffuse Large B-cell Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight [https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Diffuse Large B-cell Lymphoma Drugs Under Different Phases of Clinical Development Include:

*
UBX-303: Ubix Therapeutics

*
OPB-111077: Otsuka Pharmaceutical Co., Ltd

*
BMF-219: Biomea Fusion Inc

*
AUTO3: Autolus Limited

*
Abexinostat: Xynomic Pharmaceuticals, Inc.

*
Poseltinib: Hanmi Pharmaceutical

*
Maveropepimut: S IMV Inc.

*
Brentuximabvedotin: Seagen Inc.

*
Odronextamab: Zai Lab

*
Mosunetuzumab: Genentech

Diffuse Large B-cell Lymphoma Route of Administration

Diffuse Large B-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical.

*
Molecule Type

Diffuse Large B-cell Lymphoma Molecule Type

Diffuse Large B-cell Lymphoma Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

*
Product Type

Diffuse Large B-cell Lymphoma Pipeline Therapeutics Assessment

*
Diffuse Large B-cell Lymphoma Assessment by Product Type

*
Diffuse Large B-cell Lymphoma By Stage and Product Type

*
Diffuse Large B-cell Lymphoma Assessment by Route of Administration

*
Diffuse Large B-cell Lymphoma By Stage and Route of Administration

*
Diffuse Large B-cell Lymphoma Assessment by Molecule Type

*
Diffuse Large B-cell Lymphoma by Stage and Molecule Type

DelveInsight's Diffuse Large B-cell Lymphoma Report covers around 75+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Diffuse Large B-cell Lymphoma product details are provided in the report. Download the Diffuse Large B-cell Lymphoma pipeline report to learn more about the emerging Diffuse Large B-cell Lymphoma therapies [https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Diffuse Large B-cell Lymphoma Therapeutics Market include:

Key companies developing therapies for Diffuse Large B-cell Lymphoma are - AstraZeneca, Bristol-Myers Squibb, Seattle Genetics/Takeda, ADC Therapeutics, SymBio Pharmaceuticals, Denovo Biopharma, Merck, Amgen, TG Therapeutics, Bayer and others.

Diffuse Large B-cell Lymphoma Pipeline Analysis:

The Diffuse Large B-cell Lymphoma pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-cell Lymphoma with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-cell Lymphoma Treatment.

*
Diffuse Large B-cell Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Diffuse Large B-cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-cell Lymphoma market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Diffuse Large B-cell Lymphoma drugs and therapies [https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Diffuse Large B-cell Lymphoma Pipeline Market Drivers

*
Increasing Prevalence of DLBCL, increased research and development and CAR-T therapies are some of the important factors that are fueling the Diffuse Large B-cell Lymphoma Market.

Diffuse Large B-cell Lymphoma Pipeline Market Barriers

*
However, high cost of treatment, aggressive disease biology and geriatric vulnerability and other factors are creating obstacles in the Diffuse Large B-cell Lymphoma Market growth.

Scope of Diffuse Large B-cell Lymphoma Pipeline Drug Insight

*
Coverage: Global

*
Key Diffuse Large B-cell Lymphoma Companies: Ubix Therapeutics, Otsuka Pharmaceutical Co., Ltd, Biomea Fusion Inc, Autolus Limited, Xynomic Pharmaceuticals, Inc., Hanmi Pharmaceutical, S IMV Inc. Seagen Inc., Zai Lab, Genentech, and others

*
Key Diffuse Large B-cell Lymphoma Therapies: UBX-303, OPB-111077, BMF-219, AUTO3, Abexinostat, Poseltinib, Maveropepimut, Brentuximabvedotin, Odronextamab, Mosunetuzumab, and others

*
Diffuse Large B-cell Lymphoma Therapeutic Assessment: Diffuse Large B-cell Lymphoma current marketed and Diffuse Large B-cell Lymphoma emerging therapies

*
Diffuse Large B-cell Lymphoma Market Dynamics: Diffuse Large B-cell Lymphoma market drivers and Diffuse Large B-cell Lymphoma market barriers

Request for Sample PDF Report for Diffuse Large B-cell Lymphoma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Diffuse Large B-cell Lymphoma Report Introduction

2. Diffuse Large B-cell Lymphoma Executive Summary

3. Diffuse Large B-cell Lymphoma Overview

4. Diffuse Large B-cell Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Diffuse Large B-cell Lymphoma Pipeline Therapeutics

6. Diffuse Large B-cell Lymphoma Late Stage Products (Phase II/III)

7. Diffuse Large B-cell Lymphoma Mid Stage Products (Phase II)

8. Diffuse Large B-cell Lymphoma Early Stage Products (Phase I)

9. Diffuse Large B-cell Lymphoma Preclinical Stage Products

10. Diffuse Large B-cell Lymphoma Therapeutics Assessment

11. Diffuse Large B-cell Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Diffuse Large B-cell Lymphoma Key Companies

14. Diffuse Large B-cell Lymphoma Key Products

15. Diffuse Large B-cell Lymphoma Unmet Needs

16 . Diffuse Large B-cell Lymphoma Market Drivers and Barriers

17. Diffuse Large B-cell Lymphoma Future Perspectives and Conclusion

18. Diffuse Large B-cell Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diffuse-large-bcell-lymphoma-pipeline-2025-fda-updates-therapy-innovations-and-clinical-trial-landscape-analysis-by-delveinsight-xynomic-pharma-hanmi-pharma-s-imv-inc-seagen]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.